0QAJ Stock Chart & Stats
€2.38
€0.09(13.42%)
At close: 4:00 PM EST
€2.38
€0.09(13.42%)
Day’s Range― - ―
52-Week Range€1.44 - €4.46
Previous CloseN/A
Volume68.68K
Average Volume (3M)24.78K
Market Cap
€724.84M
Enterprise Value€1.09K
Total Cash (Recent Filing)€174.90M
Total Debt (Recent Filing)€21.80M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Oct 28, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding314,388,800
10 Day Avg. Volume11,603
30 Day Avg. Volume24,780
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€3.59M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Equity-backed Balance SheetLow debt relative to equity reduces solvency pressure and gives DBV more flexibility than a highly leveraged biotech. An equity-supported asset base can help sustain development activity through funding cycles, although it does not eliminate the need for future financing.
Focused EPIT Technology PlatformA focused platform and lead candidate provide strategic coherence around immune-mediated disease treatment. If clinical development succeeds, the technology could support a differentiated product offering and create a foundation for broader development beyond a single program.
Net Losses Have Not Meaningfully WorsenedRelative stability in net losses suggests the company has not experienced clear additional deterioration in its earnings profile versus the prior period. This is a limited positive, but maintaining loss levels can support more predictable planning while clinical programs advance.
Bears Say
No Commercial Product RevenueMinimal revenue means DBV currently lacks a proven commercial engine to fund research and development. Until a therapy is approved and launched, operating performance will remain dependent on clinical progress and access to external capital rather than recurring customer sales.
Severe And Persistent Operating LossesLarge operating and net losses indicate that the current business model is far from self-sustaining. Continued losses reduce shareholder capital over time, limit internal reinvestment capacity, and make future earnings dependent on successful development, approval, and commercialization.
Heavy Ongoing Cash Burn And Financing DependenceThe magnitude of negative operating and free cash flow creates a durable need for additional funding to maintain operations and clinical development. Reliance on equity, licensing, debt, or similar financing can dilute shareholders or constrain strategic flexibility if capital access weakens.
DBV Technologies News
0QAJ FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest share price was €1.44 and its highest was €4.46 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €724.84M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is Oct 28, 2026 which is in 51 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Jul 16, 2026. The company reported -€0.021 earnings per share for the quarter, missing the consensus estimate of -€0.019 by -€0.002.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Overvalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.02.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 314,388,800 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.021 in its last earnings report, missing expectations of -€0.019. Following the earnings report the stock price went down -9.328%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in GB:0QAJ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.